Skip to main content
. Author manuscript; available in PMC: 2023 Sep 1.
Published in final edited form as: Clin Cancer Res. 2023 Mar 1;29(5):838–842. doi: 10.1158/1078-0432.CCR-22-2036

Table 2:

ORR per RECIST 1.1 as assessed by IRC

Efficacy Parameter N = 107
ORR (95% CI) 36% (27, 45)
 Complete response n=3 2.8%
 Partial response n=35 33%
Median DoR (months) (95% CI)a 9.1 (6.0, 14.5)
Patients with DoR ≥ 6 months, n (%) 24 (63%)
Patients with DoR ≥ 12 months, n (%) 7 (18%)
a

The 95% confidence interval (CI) was calculated using the Brookmeyer and Crowley’s method.

Note: Data are by RECIST v1.1 per IRC, and all responses were confirmed.